ProfSiowMingLee

🎉Good news! IPSOS MS finally appeared today in the Lancet! Thank you to all the global investigators, patients and their families who participated in the trial. An important study showing meaningful increased survival with atezolizumab immunotherapy. shorturl.at/PTZ34

A Lancet Oncology piece on the MHRA-NICE aligned pathway and its potential to speed up NHS access to cancer medicines. In oncology, where timely access matters, closer alignment bet regulation and appraisal could make a real difference to patients. thelancet.com/journals/lanon…

🔬A welcome achievement for the UCLH research team in recruiting the first European participant. Pleased to see this recognised. An important trial for patients with advanced KRAS G12C Mutation NSCLC. uclh.nhs.uk/news/uclh-recr…

Good to hear atezolizumab immunotherapy alone highlighted as the only treatment recommended for poor PS NSCLC patients — based on the IPSOS trial. 👍

🙏 Grateful to see our “Toripalimab for ES-SCLC” commentary — first shared on 25 Sept — featured on 29 Sept 2025 in OncoDaily’s “10 Must-Read Posts in Immuno-Oncology This Week.”

ES-SCLC: charting the future of immunotherapy. Our commentary on toripalimab (EXTENTORCH) in the global trial landscape: ✅ OS benefit in Chinese trials 🌏 ✅ Need for global validation 📊 ✅ Role of HLA & biomarkers in future trials 🧬 Read👉shorturl.at/joWr6 #SCLC #IO

🌍 Honoured to speak on mRNA cancer vaccines at @globalhealthexh 2025 — a truly global platform bringing together pharma, global healthcare leaders and providers and academic innovators, amid a vibrant exhibition Great to meet the @UCL_Business team at their stand. #GlobalHealth

📢 Our full IPSOS brief report is now published online in @JTOonline ✨📄 Phase III: post hoc validation of platinum-ineligible NSCLC pts 🫁 Free access for 50 days 🔗 bit.ly/4oDwCz0 Key analysis underpinning EMA approval & building on the practice-changing IPSOS trial

🚀Off-the-shelf KRAS cancer vaccine shows promise in pancreatic & colorectal cancer. 💡 Potential in KRAS mut NSCLC – possibly ↓ SEs vs KRAS inhibitors, + CPI ± chemo combos. 📰 Covered in The Guardian, incl. potential future NSCLC trials: bit.ly/3JxkxLC

📸 Great memories from the #ESMOat50 Meeting in Nice – celebrating ESMO's 50th anniversary with colleagues, leaders and those who shaped its early years. 🙏Many thanks to @myESMO for the invitation, an excellent programme, and for sharing these photos!

🇬🇧 A potential new era for personalised mRNA cancer treatment. UK becomes the first country to pass a law enabling bedside or near-patient preparation of individualised cancer therapies — a major reg step by MHRA to cut delays ⏳ (not yet routine) Link: bit.ly/3HjpxD3

@OncoAlert 🌍🩺Thanks @OncoAlert for highlighting IPSOS - the first trial to show IO benefit in platinum doublet-unfit NSCLC pts, a major unmet NSCLC population excluded from all 1L IO pivotal trials. This post-hoc further defines the sPI population and guides real-world treatment.

Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study buff.ly/0x0aPbH A post hoc subanalysis of the Phase III IPSOS trial evaluated a refined subgroup of patients with advanced #NSCLC who were ineligible for platinum-based chemotherapy due to factors such as advanced age, poor performance status, or comorbidities. Among this selected platinum-ineligible (sPI) population, first-line treatment with atezolizumab demonstrated improved overall survival, fewer severe treatment-related adverse events, and better quality of life compared to single-agent chemotherapy. #LungCancer These findings support the use of atezolizumab in this vulnerable population and suggest a potential framework for defining platinum ineligibility in clinical practice. @peters_solange @MartinReck2 @dmavicente @caliraf @PalmeroRamon76 @DrSanjayPopat @ProfSiowMingLee #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua Ping OncoAlert #LungCancer Faculty @ChristianRolfo @GlopesMd @NarjustFlorezMD @StephenVLiu @bmassutis @Tony_Calles @s_couraud @UmbertoMalapel1 @g_mountzios @CharuAggarwalMD @christine_lovly @jillfeldman4 @bensolomon1 @alexdrilon @JordiRemon @DrJNaidoo @Latinamd @JulienMazieres

📢Now in Pre-proof (JTO): Post-hoc IPSOS in NSCLC pts unsuitable for platinum-doublet chemo. 🟢89% met sPI criteria (Venn) 📈Atezolizumab improved OS vs chemo (HR 0.78), safety & QoL. Key data behind EMA approval, building on practice-changing IPSOS trial rb.gy/53nyez

The Immune System in Cancer: Its Roles and How We Can Harness It | Technology Networks technologynetworks.com/tn/articles/th…

🙏 Honored to be invited to the 10th @EconomistImpact World Cancer Series Europe in Brussels to discuss how mRNA cancer vaccines could help shape the next era of cancer treatment—interviewed by @E_Sukkar, among health policymakers, pharma leaders & cancer experts. #CancerVaccines

@Seamusoreilly18 @curijoey @EMittendorfMD @BCRFcure @BIGxResearch @nlinmd 🙏Thank you, Seamus, for your kind words and for the kind invitation to speak. It was a real honour to contribute to this important annual #BIGNCTN meeting. Inspired by the science and the courage of our patients.

This was an inspiring talk @ProfSiowMingLee 👏👏👏 Lung cancer therapy transformed ✅ Synergy with mRNA vaccines ✅ The ambition of 🇬🇧 cancer research✅ The 💪courage of patients ✅ 🙏@curijoey @EMittendorfMD for chairing @BCRFcure @BIGxResearch @nlinmd

🙏 Honored to speak at the #BIGNCTN in Chicago with DavidBraun & @HaanenJohn. Grateful to share lung cancer vaccine insights & join the discussion on the potential of #CancerVaccines & #CellularTherapies with breast cancer leaders inc @nlinmd @Seamusoreilly18 & GiuseppeCurigliano

💊 First-line atezolizumab shows benefit in NSCLC patients unfit for platinum-doublet chemotherapy. A plain language summary of the IPSOS trial is now available. 👉 Read more here: bit.ly/4kv1LSo #NSCLC #PoorPS #Immunotherapy

Deeply grateful to @FedericoCappuz1 and team for the honour of attending #RomeLung25 in the magnificent city of Rome—made even more historic by the election of a new Pope. Inspiring to connect with global colleagues and discuss the latest advances in lung cancer treatment.

💊🔬Grateful to see our research on Hydroxychloroquine for lung cancer featured by @uclh. Thank you to the hard work and collaboration of teams and investigators across UK to deepen our understanding of HCQ’s role in lung cancer. #CancerResearch #DrugDev #HydroxyChloroquine

📣🔬Our Study 15 results are now out! This is the 1️⃣st & only randomised trial with Hydroxychloroquine (HCQ) for SCLC. Combining HCQ with 1L platinum chemo didn’t improve PFS/OS, was assoc. with more G3/4 AEs, & fewer completed 4 cycles. Link: t.ly/KkL2M